Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Metrics to compare | CING | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCINGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.2x | −4.1x | −0.7x | |
PEG Ratio | −0.02 | −0.08 | 0.00 | |
Price/Book | 4.0x | 0.6x | 2.6x | |
Price / LTM Sales | - | 1.9x | 3.4x | |
Upside (Analyst Target) | - | 221.4% | 37.8% | |
Fair Value Upside | Unlock | 3.2% | 5.3% | Unlock |